Emerging Markets Remain Strong For Sanofi
This article was originally published in PharmAsia News
Sanofi has been so effective at building up its business in emerging markets these now account for around a third of the French group's total sales, and provided another quarter of strong growth despite some vaccines weakness.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.